Pill that slashes risk of breast cancer recurring to be available on NHS

Pill that slashes risk of breast cancer recurring to be available on NHS

Ribociclib (known by the brand name Kisqali) targets specific proteins that contribute to cancer cell growth

Higher breast cancer risk among more educated women, study finds

Later and fewer pregnancies, as well as alcohol consumption, partially explain the phenomenon, according to a large study involving over 300,000 women.

NICE Recommends Ribociclib for High-Risk Early Breast Cancer

NICE has recommended the targeted drug ribociclib as an adjuvant option for patients with high-risk early breast cancer, potentially benefiting up to 4000 people in England.

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the International Agency for Research on Cancer...

Ribociclib With Nonsteroidal Aromatase Inhibitor Does Not Reduce Quality of Life in HR+/HER2- Early Breast Cancer

Patients in both arms achieved statistically significant rates of compliance up to 97%.